Phuoc T. Tran, MD, PhD, University of Maryland, College Park, MD, shares Highlights in prostate cancer from the ASCO GU Cancers Symposium 2023, focusing on PARP inhibitors in castration-resistant prostate cancer (CRPC), such as with rucaparib, olaparib or niraparib. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.